MedTrace Logo

Cannabidiol, Morphine, Pain

NCT04030442 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-02-29

No results posted yet for this study

Summary

The purpose of the proposed study is to investigate the interaction of cannabidiol (CBD) and morphine effects on pain sensitivity. Cannabidiol is a cannabinoid (similar to cannabis, or marijuana) present in marijuana that alters some of the effects of marijuana.

Conditions

Interventions

DRUG

Immediate-release Oral Morphine Sulfate Tablets

0 mg Immediate release oral morphine; 15 mg Immediate release oral morphine; 30 mg Immediate release oral morphine; Randomized between sessions

OTHER

Thermal and Pressure Nociceptive Sensitivity

Primary outcome measures of pain threshold and tolerance.

Sponsors & Collaborators

  • Wayne State University

    lead OTHER

Principal Investigators

  • Leslie Lundahl, PhD · Wayne State University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2025-01-26
Completion
2025-01-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04030442 on ClinicalTrials.gov